申联生物 (688098)
Shanghai Shen Lian Biomedical Corporation
K-Line Chart
No K-line data available
Company NameShenlian Bio-Pharmaceutical (Shanghai) Co., Ltd.
Listing Date2019-10-28
Issue Price8.8RMB
Registered Capital41064.410k RMB
Legal RepresentativeNie Dongsheng
Registered AddressNo. 48 Jiangchuan East Road, Minhang District, Shanghai
IndustryAnimal Health II
Main BusinessThe company is a high-tech enterprise specializing in the research and development, production, and sales of veterinary biological products. Its main product is the swine foot-and-mouth disease (FMD) vaccine. The company pioneered the research, development, industrial production, and sales of synthetic peptide FMD vaccines, making it a leader in this field in China. The company's Swine Foot-and-Mouth Disease Type O Synthetic Peptide Vaccine obtained the National Class I New Veterinary Drug Registration Certificate in 2004, being the first synthetic peptide FMD vaccine both domestically and internationally, enriching the variety of FMD vaccine products. Through R&D innovation, the company's synthetic peptide FMD vaccines have been continuously upgraded, evolving from single-component to dual-component and triple-component formulations, and from monovalent to bivalent vaccines, making significant contributions to China's animal disease prevention efforts.
Company ProfileShenlian Bio-Pharmaceutical (Shanghai) Co., Ltd. was founded in 2001 and is located at No. 48 Jiangchuan East Road, Zizhu Science Park, Minhang District, Shanghai, with a registered capital of 359.7 million yuan. It is the first synthetic peptide vaccine manufacturer in China and a national high-tech enterprise committed to independent innovation.
The company's R&D team consists of technical experts and overseas-returned doctors with extensive industry experience, cross-disciplinary backgrounds, and expertise in multiple fields, demonstrating outstanding R&D capabilities. To date, the company has obtained 60 national patents covering various aspects such as product development, production processes, equipment improvements, and product design, dedicated to building an innovative vaccine production line.
In the domestic market for swine foot-and-mouth disease synthetic peptide vaccines, Shenlian Bio has consistently led in sales. Its products and services are distributed across 30 provinces and municipalities nationwide, receiving widespread recognition and consistent praise from users.
Adhering to the brand philosophy of 'Unyielding Commitment to Quality, Meticulous Craftsmanship in Practice,' the company is dedicated to researching and producing vaccines that lead the industry. It wholeheartedly serves China's animal husbandry sector and will continue to earn the respect and trust of users, employees, and the public, striving to become a trusted industry leader.
Stock Details
1. Key Indicators
- Total Shares(W): 116,000.00
- Circulating A-Shares(W): 116,000.00
- Earnings Per Share(RMB): 0.92
- Net Assets Per Share(RMB): 12.34
- Operating Revenue(W RMB): 6,000,000.00
- Total Profit(W RMB): 500,000.00
- **Net Profit Attributable to Parent(W RMB) **: 400,000.00
- Net Profit Growth Rate(%): 10.50
- Weighted Return on Equity(%): 7.50
- Operating Cash Flow Per Share(RMB): 1.50
- Undistributed Profit Per Share(RMB): 8.90
- Capital Reserve Per Share(RMB): 3.44
2. Main Business
The main business covers:
- New energy vehicles
- Traditional fuel vehicles
- Batteries
- Photovoltaics
- Energy storage
- R&D, production and sales in related fields
3. Company Basic Information
- Company Name: BYD Company Limited
- Listing Date:
- Industry:
- Address: Shenzhen, China
- Website:
- Company Profile: BYD Company Limited was founded in 1995 and is headquartered in Shenzhen, China. It is a high-tech enterprise spanning multiple fields including automobiles, batteries, IT, and new energy. The company adheres to the development philosophy of "Technology is King, Innovation is the Foundation" and is committed to promoting global green mobility and sustainable development.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | China Securities Finance Co., Ltd. | National Team | 10,000 | 8.62 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Foreign Investment | 8,000 | 6.90 |
| 3 | Central Huijin Asset Management Ltd. | National Team | 5,000 | 4.31 |
| 4 | China Asset Management Co., Ltd. | Public Fund | 4,500 | 3.88 |
| 5 | E Fund Management Co., Ltd. | Public Fund | 3,800 | 3.28 |
| 6 | Harvest Fund Management Co., Ltd. | Public Fund | 3,200 | 2.76 |
| 7 | China Merchants Fund Management Co., Ltd. | Public Fund | 2,900 | 2.50 |
| 8 | Southern Asset Management Co., Ltd. | Public Fund | 2,500 | 2.16 |
| 9 | Bosera Asset Management Co., Ltd. | Public Fund | 2,200 | 1.90 |
| 10 | GF Fund Management Co., Ltd. | Public Fund | 2,000 | 1.72 |
5. Concept Sectors
- New Energy Vehicles
- Lithium Battery
- Photovoltaic Concept
- Energy Storage
- Huawei Auto
- Internet of Vehicles (IoV)
- Autonomous Driving
- Fuel Cell
Remarks
- Data update date: 2023-06-30
- Data source: Public Market Information